Business
Amex Logo
American Express logo in front of a stock chart (Getty Images)

Amex buys all the restaurant reservation apps so it can save seats for its ritziest cardholders

American Express spent $400 million to give more seats to its highest-paying members.

Jack Raines

A couple of weeks ago, American Express announced that it acquired Tock, a high-end reservation and table management app that offers bookings at more than 7,000 restaurants and wineries, for an astounding $400 million, or $57,142 per restaurant that it’s partnered with. This comes five years after it purchased Resy for ~$200 million.

Why would a credit card company spend more than half a billion dollars on two restaurant reservation apps? So it can reserve a subset of reservations for holders of its most expensive credit cards. From Amex’s press release:

“Restaurants are one of our largest Card Member spending categories within Travel and Entertainment, with $100 billion in volume in 2023,” said Howard Grosfield, President, U.S. Consumer Services, American Express. “We’ve been offering unique dining benefits, exclusive access, and special experiences to our Card Members for years through Resy and Global Dining Access by Resy. Now, we can connect even more premium customers with the most exciting restaurants, while providing merchants and restaurants more technology to help their businesses thrive.”

According to American Express’s website, its “Global Dining Access by Resy,” where the company offers exclusive reservations to different restaurants, is available to account holders of some of Amex’s most expensive cards, such as its Hilton Honors Aspire Card ($550 annual fee), Platinum Card ($695 annual fee), Delta SkyMiles Reserve Card ($695 annual fee), and Centurion Card ($10,000 initiation fee, $5,000 annual fee).

This really is a galaxy brain move by American Express. Apps have made it virtually impossible to get a reservation at half of New York’s nice restaurants, but if you own the apps, you can then save a portion of available reservations each week for your highest-paying customers, enticing new diners to shell out $695 for a Platinum Card.

“Oh, you can’t get a reservation at 4 Charles Prime Rib? That sucks. We have 20 tables available this week if you upgrade from your Gold Card. It’ll only cost you $695.” For some diners who are already considering paying $1000 for a table at Carbone, it’s a bargain!  If American Express can upsell enough customers, then the $400 million sticker price will more than pay for itself.

My takeaway from this is that, if you’re a startup founder, perhaps you should focus on building a reservation service for Michelin Star restaurants, not the 47th Gen AI platform of 2024.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.